172 related articles for article (PubMed ID: 10928078)
21. Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo.
Nagai N; Ogata H
Cancer Chemother Pharmacol; 1997; 40(1):11-8. PubMed ID: 9137523
[TBL] [Abstract][Full Text] [Related]
22. Pre-clinical study of the epinephrine-cisplatin association for the treatment of intraperitoneal carcinomatosis.
Favoulet P; Magnin G; Guilland JC; Beltramo JL; Osmak L; Benoit L; Rat P; Douvier S; Duvillard C; Chauffert B
Eur J Surg Oncol; 2001 Feb; 27(1):59-64. PubMed ID: 11237494
[TBL] [Abstract][Full Text] [Related]
23. Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosis.
Molucon-Chabrot C; Isambert N; Benoit L; Zanetta S; Fraisse J; Guilland JC; Royer B; Monin-Baroille P; Flesch M; Fargeot P; Coudert B; Mayer F; Fumoleau P; Chauffert B
Anticancer Drugs; 2006 Nov; 17(10):1211-7. PubMed ID: 17075321
[TBL] [Abstract][Full Text] [Related]
24. Intracavitary administration: pharmacokinetic advantages of macromolecular anticancer agents against peritoneal and pleural carcinomatoses.
Kimura M; Konno T; Miyamoto Y; Kojima Y; Maeda H
Anticancer Res; 1998; 18(4A):2547-50. PubMed ID: 9703908
[TBL] [Abstract][Full Text] [Related]
25. Intrapleural topical application of cisplatin with the surgical carrier Vivostat increases the local drug concentration in an immune-competent rat model with malignant pleuromesothelioma.
Lardinois D; Jung FJ; Opitz I; Rentsch K; Latkoczy C; Vuong V; Varga Z; Rousson V; Günther D; Bodis S; Stahel R; Weder W
J Thorac Cardiovasc Surg; 2006 Mar; 131(3):697-703. PubMed ID: 16515926
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) and cisplatin given i.v. and i.p. in the rat.
Vadiei K; Siddik ZH; Khokhar AR; al-Baker S; Sampedro F; Perez-Soler R
Cancer Chemother Pharmacol; 1992; 30(5):365-9. PubMed ID: 1505075
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of oxaliplatin during open versus laparoscopically assisted heated intraoperative intraperitoneal chemotherapy (HIPEC): an experimental study.
Gesson-Paute A; Ferron G; Thomas F; de Lara EC; Chatelut E; Querleu D
Ann Surg Oncol; 2008 Jan; 15(1):339-44. PubMed ID: 17943387
[TBL] [Abstract][Full Text] [Related]
28. Distribution of intraperitoneal chemotherapy into the pleural cavity.
Vaccarello L; Berghella V; Rubin SC; Hoskins WJ
Obstet Gynecol; 1994 Oct; 84(4 Pt 2):714-7. PubMed ID: 9205461
[TBL] [Abstract][Full Text] [Related]
29. Impact of carrier solutions on pharmacokinetics of intraperitoneal chemotherapy.
Pestieau SR; Schnake KJ; Stuart OA; Sugarbaker PH
Cancer Chemother Pharmacol; 2001 Mar; 47(3):269-76. PubMed ID: 11320672
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and tissue distribution of iv injection of polyphase liposome-encapsulated cisplatin (KM-1) in rats.
Wang S; Mi JB; Li YZ; Chang WB; Ci YX; Zhao MZ; Zhao YK; Zhu LY; Xu G
Acta Pharmacol Sin; 2003 Jun; 24(6):589-92. PubMed ID: 12791187
[TBL] [Abstract][Full Text] [Related]
31. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma.
Zamboni WC; Gervais AC; Egorin MJ; Schellens JH; Zuhowski EG; Pluim D; Joseph E; Hamburger DR; Working PK; Colbern G; Tonda ME; Potter DM; Eiseman JL
Cancer Chemother Pharmacol; 2004 Apr; 53(4):329-36. PubMed ID: 14673619
[TBL] [Abstract][Full Text] [Related]
32. Low in vivo toxicity of a novel cisplatin-ursodeoxycholic derivative (Bamet-UD2) with enhanced cytostatic activity versus liver tumors.
Dominguez MF; Macias RI; Izco-Basurko I; de La Fuente A; Pascual MJ; Criado JM; Monte MJ; Yajeya J; Marin JJ
J Pharmacol Exp Ther; 2001 Jun; 297(3):1106-12. PubMed ID: 11356935
[TBL] [Abstract][Full Text] [Related]
33. Monoclonal antibody delivery to intraperitoneal tumors in rats: effects of route of administration and intraperitoneal solution osmolality.
Flessner MF; Dedrick RL
Cancer Res; 1994 Aug; 54(16):4376-84. PubMed ID: 8044785
[TBL] [Abstract][Full Text] [Related]
34. [Safety and efficacy of hypotonic CDDP intraperitoneal administration for gastric cancer with peritoneal dissemination].
Bamba T; Kanda T; Ohashi M; Hanyu T; Sakamoto K; Ishikawa T; Yajima K; Makino S; Tanabe T; Kosugi S; Hatakeyama K
Gan To Kagaku Ryoho; 2005 Oct; 32(11):1695-7. PubMed ID: 16315912
[TBL] [Abstract][Full Text] [Related]
35. [A study on the model of tuberculous pleurisy and intrapleural inflammatory and immunological responses in rats].
He Q; Xie CM; Tan SY; Zhang KX; Deng XH; Zhu PB; Yi XP; Zhang YL; Cai XS; Huang LJ; Liu Y
Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):117-21. PubMed ID: 15854395
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic behaviour of cisplatin in peritoneal fluid after intraperitoneal administration of cisplatin-loaded microspheres.
Tamura T; Imai J; Matsukawa Y; Horikiri Y; Suzuki T; Yoshino H; Ike O
J Pharm Pharmacol; 2001 Oct; 53(10):1331-9. PubMed ID: 11697540
[TBL] [Abstract][Full Text] [Related]
37. Role of Na+, K+-ATPase alpha1 subunit in the intracellular accumulation of cisplatin.
Kishimoto S; Kawazoe Y; Ikeno M; Saitoh M; Nakano Y; Nishi Y; Fukushima S; Takeuchi Y
Cancer Chemother Pharmacol; 2006 Jan; 57(1):84-90. PubMed ID: 16044341
[TBL] [Abstract][Full Text] [Related]
38. Hyperthermia modifies pharmacokinetics and tissue distribution of intraperitoneal melphalan in a rat model.
Glehen O; Stuart OA; Mohamed F; Sugarbaker PH
Cancer Chemother Pharmacol; 2004 Jul; 54(1):79-84. PubMed ID: 15048586
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites.
Verschraagen M; Boven E; Ruijter R; van der Born K; Berkhof J; Hausheer FH; van der Vijgh WJ
Clin Pharmacol Ther; 2003 Aug; 74(2):157-69. PubMed ID: 12891226
[TBL] [Abstract][Full Text] [Related]
40. Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics.
de Lima Vazquez V; Stuart OA; Mohamed F; Sugarbaker PH
Cancer Chemother Pharmacol; 2003 Aug; 52(2):108-12. PubMed ID: 12759776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
